5,064 results match your criteria: "Paoli Calmettes Institute; INSERM UMR599 232 Bd[Affiliation]"

DOK1 and DOK2 regulate CD8 T cell signaling and memory formation without affecting tumor cell killing.

Sci Rep

July 2024

Centre de Recherche en Cancérologie de Marseille, CRCM, Immunity and Cancer Team, Institut Paoli-Calmettes, Inserm, CNRS, Aix Marseille University, Marseille, France.

Targeting intracellular inhibiting proteins has been revealed to be a promising strategy to improve CD8 T cell anti-tumor efficacy. Here, we are focusing on intracellular inhibiting proteins specific to TCR signaling: DOK1 and DOK2 expressed in T cells. We hypothesized that depletion of intracellular inhibition checkpoint DOK1 and DOK2 could improve CD8 T-cell based cancer therapies.

View Article and Find Full Text PDF
Article Synopsis
  • The LSC-17 score, based on a gene expression profile related to stemness, indicates poor outcomes in acute myeloid leukemia (AML), but how leukemic stem cell anchoring affects disease progression is unclear.
  • Conditional inactivation of the adhesion molecule JAM-C in a mouse model of AML showed that its deletion affected HSC expansion but not disease initiation or progression, revealing insights into leukemic cell behavior in the bone marrow niche.
  • Findings suggest that the AP-1/TNF-α gene signature, which correlated with different prognosis in AML, provides additional prognostic information alongside the LSC-17 score, highlighting the importance of niche interactions in leukemia.
View Article and Find Full Text PDF
Article Synopsis
  • The Euchromatic Histone Methyl Transferase Protein 2 (EHMT2/G9a) is important for regulating gene expression related to organ health, influencing inflammation and potentially cancer development.
  • Recent studies indicate that deactivating EHMT2 in mouse pancreatic cells changes gene expression linked to damage and inflammation, which may enhance susceptibility to injury.
  • The research uses advanced techniques to analyze how the pancreas responds to damage, revealing that loss of EHMT2 leads to an escalated inflammatory response by altering the local cell environment, suggesting its role in both cancer suppression and inflammatory diseases.
View Article and Find Full Text PDF

In vivo organoid growth monitoring by stimulated Raman histology.

Npj Imaging

June 2024

Aix Marseille Univ, CNRS, Centrale Med, Institut Fresnel, Marseille, France.

Patient-derived tumor organoids have emerged as a crucial tool for assessing the efficacy of chemotherapy and conducting preclinical drug screenings. However, the conventional histological investigation of these organoids necessitates their devitalization through fixation and slicing, limiting their utility to a single-time analysis. Here, we use stimulated Raman histology (SRH) to demonstrate non-destructive, label-free virtual staining of 3D organoids, while preserving their viability and growth.

View Article and Find Full Text PDF

Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.

Exp Mol Med

July 2024

INSERM U1086 ANTICIPE (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine for Ovarian Cancers), Université de Caen Normandie, Caen, France.

Over the past decade, the emergence of patient-derived tumor organoids (PDTOs) has broadened the repertoire of preclinical models and progressively revolutionized three-dimensional cell culture in oncology. PDTO can be grown from patient tumor samples with high efficiency and faithfully recapitulates the histological and molecular characteristics of the original tumor. Therefore, PDTOs can serve as invaluable tools in oncology research, and their translation to clinical practice is exciting for the future of precision medicine in oncology.

View Article and Find Full Text PDF

Objective: To report the results of a multicenter cohort of preoperative brachytherapy (PBT) for treatment of early-stage cervical cancer (ESCC).

Methods: A retrospective analysis was conducted among five French comprehensive cancer centers on behalf of the SFRO Brachytherapy Group to examine the outcome of patients with ESCC who received PBT between 2001 and 2019 because of adverse prognostic factors (tumor size >2 cm, presence of lymphovascular invasion, adenocarcinoma).Brachytherapy was followed 4-8 weeks later by surgery.

View Article and Find Full Text PDF

Although intensive induction chemotherapy (IC) remains the standard of care for younger patients with acute myeloid leukemia (AML), hypomethylating agents + venetoclax (HMA/VEN) can lead to durable remission among older patients with nucleophosmin 1 (NPM1) mutations. Whether IC or HMA/VEN is superior in patients aged ≥60 years with NPM1-mutant AML is unknown. We performed an international, multicenter retrospective cohort study of 221 patients (147 IC and 74 HMA/VEN) with previously untreated NPM1-mutant AML.

View Article and Find Full Text PDF

Background And Objective: A hilar location for a renal tumour is sometimes viewed as a limiting factor for safe partial nephrectomy. Our aim was to evaluate perioperative, oncological, and functional outcomes of robot-assisted partial nephrectomy (RAPN) for hilar tumours (RAPN-H) in comparison to RAPN for nonhilar tumours (RAPN-NH).

Methods: We conducted an observational, multicentre cohort study using prospectively collected data from the French Research Network on Kidney Cancer (UroCCR).

View Article and Find Full Text PDF

Background And Objective: Abiraterone acetate (abiraterone) plus prednisone is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Our aim was to evaluate the efficacy and safety of pembrolizumab plus abiraterone in mCRPC.

Methods: In cohort D of the phase 1b/2 KEYNOTE-365 study (NCT02861573), patients were chemotherapy-naïve, had disease progression ≤6 mo before screening, and had either not received prior next-generation hormonal agents for mCRPC or had received prior enzalutamide for mCRPC and had disease progression or became intolerant to enzalutamide.

View Article and Find Full Text PDF

Endometrioid ovarian carcinoma landscape: pathological and molecular characterization.

Mol Oncol

October 2024

Department of Medical Oncology, Aix-Marseille Univ, Inserm, CNRS, Institut Paoli-Calmettes, Marseille, France.

Endometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter study involved patients from three European centers.

View Article and Find Full Text PDF

Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer.

Br J Cancer

September 2024

Department of Medical Oncology, Oncopole Claudius Regaud, IUCT-O, Toulouse, France.

Background: Current guidelines recommend that patients with HER2-low metastatic breast cancer (MBC) receive sequentially two antibody-drug conjugates (ADCs): Sacituzumab Govitecan (SG) and Trastuzumab Deruxtecan (T-DXd), despite a similar payload. However, the effectiveness of one after another is unknown.

Methods: ADC-Low is a multicentre, retrospective study evaluating the efficacy of SG and T-DXd, one after another, with or without intermediary lines of chemotherapy, in patients with HER2-low MBC.

View Article and Find Full Text PDF

Nuclear pore complexes (NPCs) have emerged as genome organizers, defining a particular nuclear compartment enriched for SUMO protease and proteasome activities, and act as docking sites for the repair of DNA damage. In fission yeast, the anchorage of perturbed replication forks to NPCs is an integral part of the recombination-dependent replication restart mechanism (RDR) that resumes DNA synthesis at terminally dysfunctional forks. By mapping DNA polymerase usage, we report that SUMO protease Ulp1-associated NPCs ensure efficient initiation of restarted DNA synthesis, whereas proteasome-associated NPCs sustain the progression of restarted DNA polymerase.

View Article and Find Full Text PDF

Empirical antifungal therapy for health care-associated intra-abdominal infection: a retrospective, multicentre and comparative study.

Ann Intensive Care

June 2024

Department of Anesthesiology and Intensive Care Unit, Nord Hospital, Assistance Publique Hôpitaux Universitaires De Marseille, Aix Marseille University, Marseille, France.

Background: Current guidelines recommend using antifungals for selected patients with health care-associated intra-abdominal infection (HC-IAI), but this recommendation is based on a weak evidence. This study aimed to assess the association between early empirical use of antifungals and outcomes in intensive care unit (ICU) adult patients requiring re-intervention after abdominal surgery.

Methods: A retrospective, multicentre cohort study with overlap propensity score weighting was conducted in three ICUs located in three medical institutions in France.

View Article and Find Full Text PDF

Background: After surgical resection of pancreatic ductal adenocarcinoma (PDAC), patients are predominantly treated with adjuvant chemotherapy, commonly consisting of gemcitabine (GEM)-based regimens or the modified FOLFIRINOX (mFFX) regimen. While mFFX regimen has been shown to be more effective than GEM-based regimens, it is also associated with higher toxicity. Current treatment decisions are based on patient performance status rather than on the molecular characteristics of the tumor.

View Article and Find Full Text PDF

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.

Am J Hematol

October 2024

Service d'hématologie, Centre Hospitalo-universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Université de Toulouse, UPS, Service d'hématologie, Toulouse, France.

Article Synopsis
  • Venetoclax-azacitidine is the standard treatment for unfit acute myeloid leukemia patients, but there is limited data on how long patients should continue therapy if they cannot tolerate it.
  • In a study analyzing patients who stopped treatment due to poor tolerance, those who discontinued showed comparable outcomes to those who continued with azacitidine alone, with median overall survival of 44 months for newly diagnosed patients.
  • The findings suggest that patients who stop treatment while in remission can have favorable outcomes, indicating a need for further controlled trials to explore optimal treatment durations.
View Article and Find Full Text PDF

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.

Haematologica

November 2024

Service d'hématologie, Institut Curie, Saint Cloud, France ; Université de Versailles Saint-Quentin (UVSQ), France; Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), U1288 Inserm/Institut Curie Centre de recherche.

View Article and Find Full Text PDF

In mammalian cells, DNA double-strand breaks are predominantly repaired by non-homologous end joining (NHEJ). During repair, the Ku70-Ku80 heterodimer (Ku), X-ray repair cross complementing 4 (XRCC4) in complex with DNA ligase 4 (X4L4) and XRCC4-like factor (XLF) form a flexible scaffold that holds the broken DNA ends together. Insights into the architectural organization of the NHEJ scaffold and its regulation by the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) were recently obtained by single-particle cryo-electron microscopy analysis.

View Article and Find Full Text PDF

The metabolic process of purple sulphur bacteria's anoxygenic photosynthesis has been primarily studied in Allochromatium vinosum, a member of the Chromatiaceae family. However, the metabolic processes of purple sulphur bacteria from the Ectothiorhodospiraceae and Halorhodospiraceae families remain unexplored. We have analysed the proteome of Halorhodospira halophila, a member of the Halorhodospiraceae family, which was cultivated with various sulphur compounds.

View Article and Find Full Text PDF

The transcription factor BACH1 regulates heme homeostasis and oxidative stress responses and promotes cancer metastasis upon aberrant accumulation. Its stability is controlled by two F-box protein ubiquitin ligases, FBXO22 and FBXL17. Here we show that the homodimeric BTB domain of BACH1 functions as a previously undescribed quaternary structure degron, which is deciphered by the two F-box proteins via distinct mechanisms.

View Article and Find Full Text PDF
Article Synopsis
  • A study is investigating whether flow cytometric analysis of myeloperoxidase expression in peripheral blood can accurately rule out myelodysplastic neoplasm (MDS), potentially reducing unnecessary bone marrow aspirations for about 35% of patients.
  • The MPO-MDS-Valid project involves recruiting 400 patients from multiple hospitals in France to validate the testing method by comparing it to established diagnoses made by experienced hematopathologists.
  • The research has been ethically approved, and results will be shared through publication to inform medical practice and improve patient care.
View Article and Find Full Text PDF

Background: CASSIOPEIA part 1 demonstrated superior depth of response and prolonged progression-free survival with daratumumab in combination with bortezomib, thalidomide, and dexamethasone (D-VTd) versus bortezomib, thalidomide, and dexamethasone (VTd) alone as an induction and consolidation regimen in transplant-eligible patients newly diagnosed with myeloma. In CASSIOPEIA part 2, daratumumab maintenance significantly improved progression-free survival and increased minimal residual disease (MRD)-negativity rates versus observation. Here, we report long-term study outcomes of CASSIOPEIA.

View Article and Find Full Text PDF

Reply to J.A. Garcia et al.

J Clin Oncol

August 2024

Susan Halabi, PhD, Duke University School of Medicine, Durham, NC; Siyuan Guo, PhD, Duke University School of Medicine, Durham, NC; Akash Roy, PhD, Medical University of South Carolina, Charleston, SC; Larysa E. Rydzewska, PhD and Peter Godolphin, PhD, University College London, London, UK; Maha Hussain, MD, Northwestern University, Chicago, IL; Catherine Tangen, PhD, Fred Hutchinson Cancer Center, Seattle, WA; Ian Thompson, MD, Christus Health, San Antonio, TX; Wanling Xie, MS, Dana Farber Cancer Institute, Boston, MA; Michael A. Carducci, MD, Johns Hopkins University, Baltimore, MD; Michael J. Morris, MD, MSKCC, New York, NY; Matthew R. Smith, MD, PhD, MGH, Boston, MA; Gwenaelle Gravis, MD, Institut Paoli-Calmettes Aix-Mareseille Université, Mareseille, France; David P. Dearnaley, MD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Paul J. Verhagen, MD, Erasmus Medical Center, Rotterdam, the Netherlands; Takayuki J. Goto, MD, Kyoto University, Japan; Nick D. James, MD, PhD, Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK; Marc E. Buyse, PhD, IDDI, Brussels, Belgium; Jayne F. Tierney, PhD, University College London, London, UK; and Christopher J. Sweeney, MD, University of Adelaide, Adelaide, Australia.

View Article and Find Full Text PDF

Fluorine magnetic resonance imaging (F-MRI) is particularly promising for biomedical applications owing to the absence of fluorine in most biological systems. However, its use has been limited by the lack of safe and water-soluble imaging agents with high fluorine contents and suitable relaxation properties. We report innovative F-MRI agents based on supramolecular dendrimers self-assembled by an amphiphilic dendrimer composed of a hydrophobic alkyl chain and a hydrophilic dendron.

View Article and Find Full Text PDF